d_risk Posted - 1 day ago

$SRDX - Surmodics Inc. Common Stock - 10K - Updated Risk Factors The 2024 10-K Risk Factor section for SRDX highlights new risks related to a pending merger, including potential termination, business uncertainties, and substantial transaction costs. Additional risks include market share challenges, reliance on third parties, economic conditions, and intellectual property issues. #Risk @Surmodics https://d-risk.ai/SRDX/10-K/2024-11-20

DonCorleone77 Posted - 2 weeks ago

$SRDX Surmodics reports Q4 EPS (13c), consensus (29c) Reports Q4 revenue $$33.23M , consensus $ $30.39M. "We are proud to deliver a strong conclusion to fiscal 2024, with total revenue growth in the fourth quarter of 19% year-over-year fueled by impressive performance in our Medical Device segment - including product revenue growth of nearly 40% year-over-year - combined with solid contributions from our IVD segment," said Gary Maharaj, President and CEO of Surmodics, Inc. "Our Medical Device segment product sales growth in the fourth quarter was driven primarily by demand for our vascular interventional products, including our Pounce Thrombectomy Platform and SurVeil DCB, as well as increased sales of our performance coating reagents." "I want to thank the Surmodics' team for their extraordinary dedication and focus in delivering strong quarterly and full-year operating results while we work to substantially comply with the FTC's Second Request."

ChessGM Posted - 2 weeks ago

$SRDX Heads up alert! Only one day until Upcoming earnings on Wednesday, 11/6/2024 for $SRDX Bearish (2.7) In a comprehensive analysis of Surmodics, Inc. (SRDX), the company is currently navigating a complex landscape characterized by both regulatory advancements and market performance challenges. Recently, the firm announced early results from the PROWL registry study, showcasing its Pounce™ Thrombectomy System's effectiveness in treating limb ischemia. However, despite the positive implications of this development, the stock has faced pressures, notably a decline following the FDA clearance of the Pounce XL System, which was anticipated to enhance the product's market reach. Financially, Surmodics has exhibited a P/E ratio that is higher than that of its industry peers, indicating a potential overvaluation compared to expected earnings growth. The company's EPS growth remains modest, and revenue forecasts have been adjusted downward, reflecting investor concerns over the immediate financial impact of their new product lines against the backdrop of a competitive healthcare sector. These factors combine to create a cautious outlook for SRDX, as the market weighs the potential of regulatory approvals against the reality of stock performance. Looking ahead, Surmodics is expected to report earnings soon, with analysts projecting modest growth in revenue driven by the introduction of new products. Historical performance indicates volatility in earnings results, which has led to a mixed analyst consensus. Current estimates suggest a slight increase in earnings per share, but the overall sentiment remains tempered by uncertainties in the market. The upcoming earnings report will be critical in determining whether the recent product developments can translate into tangible financial results, thereby influencing investor sentiment and stock performance in the near term. - Funds were net buyers of $SRDX during the previous reporting quarter. - Top 3 funds with large holdings in $SRDX: * Soleus Capital $33MM. CGMFundRank: 57% * D. E. Shaw & Co $2MM. CGMFundRank: 85% * Trium Capital LLP $1MM. New position. CGMFundRank: 54% - Last 10 days performance: 0% - Last 30 days performance: -2% - Last 90 days performance: -8% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.

Estimize Posted - 10/28/24

Wall St is expecting 8.67% YoY revenue growth for $SRDX in Q4, up from -42.19% in Q3 [Reporting 11/06 BMO] http://www.estimize.com/intro/sr

DonCorleone77 Posted - 1 month ago

$SRDX FDA gives Surmodics clearance for Pounce XL Thrombectomy System Surmodics announced it has received U.S. Food and Drug Administration FDA 510(k) clearance for its Pounce XL Thrombectomy System..."Securing FDA clearance for the Pounce XL Thrombectomy System is a major step forward in Surmodics' pursuit of a complete mechanical thrombectomy solution for all peripheral arteries, notably critically ischemic lower extremity vessels," said Gary Maharaj, President and Chief Executive Officer of Surmodics. "The Pounce Thrombectomy Platform has already demonstrated its performance as a rapid, efficient solution for the removal of both acute and chronic thrombi and emboli in peripheral arteries without the use of thrombolytics..." Surmodics expects to initiate limited market release for the Pounce XL Thrombectomy System in the first half of 2025, with commercialization planned following the completion of the limited market release.

intratio Posted - 2 months ago

$SRDX https://www.intratio.com/stock-forecast/SRDX The machine learning model judges that this company s value will rise in the short-term and has a neutral long-term outlook

intratio Posted - 2 months ago

https://www.intratio.com/stock-forecast/SRDX Our algorithm foretells the value of this company has a good setup for the short-term and the stock price is in line with the long-term fundamentals of the company $SRDX

intratio Posted - 2 months ago

SURMODICS INC The algorithm deduces that this equity s value will gain positive momentum in the coming days and is not likely to present a long-term opportunity $SRDX

intratio Posted - 08/30/24

The predictive algorithm calculated that the value of this company will pick up steam in the upcoming days and the stock price is in line with the long-term fundamentals of the business $SRDX

Aigner_Andreas Posted - 3 months ago

TD BUY $SRDX at 39.31, Supp 36.00 Resis 41.50 R15 HiLo 83% T1Y 71 strong_buy 1.5 DIV N/A #SurModics #stocks #trading #finance #market

PenkeTrading Posted - 3 months ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of SurModics Inc. Is that bullish or bearish? $SRDX #SRDX #nasdaq #tradingsignals #technicalanalysis

OpenOutcrier Posted - 3 months ago

$SRDX (-2.0% pre) Surmodics stock on watch post FTC second request - SA https://ooc.bz/l/40047

Mergerbrief Posted - 3 months ago

$SRDX / GTCR Private Equity - Shareholder Vote $SRDX MergerBrief.com

Fullratio Posted - 3 months ago

$SRDX EBITDA margin has plunged by 85% from the previous quarter and by 60% YoY: https://fullratio.com/stocks/nasdaq-srdx/surmodics

NVDAMillionaire Posted - 07/31/24

$SRDX Surmodics, Inc. (NASDAQ:SRDX) Reports Impressive Q3 2024 Results, Raises Full-Year Guidance http://beyondspx.com/2024/07/31/surmodics-inc-nasdaqsrdx-reports-impressive-q3-2024-results-raises-full-year-guidance/

DonCorleone77 Posted - 07/31/24

$SRDX Surmodics reports Q3 EPS (27c), consensus (33c) Reports Q3 revenue $30.3M, consensus $30.01M ."Our team's focus and execution in the third quarter enabled us to deliver total revenue results consistent with the expectations shared on our most recent earnings call, benefiting from strength across multiple areas of our business," said Gary Maharaj, President and CEO of Surmodics, Inc. "Specifically, we saw strong contributions from growth in both Medical Device product revenue - driven primarily by demand for our SurVeil DCB and Pounce thrombectomy products - and performance coating royalties and license fees, along with broad-based growth in sales of our In Vitro Diagnostics products as well."

epsguid Posted - 07/31/24

$SRDX reported a loss of $0.27, consensus was ($0.31) via @eWhispers #epsbeat http://eps.sh/d/srdx

Stock_Titan Posted - 07/31/24

$SRDX Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results https://www.stocktitan.net/news/SRDX/surmodics-reports-third-quarter-of-fiscal-year-2024-financial-jff4pycahfhw.html

wohlfruchter Posted - 06/26/24

$SRDX our attorneys are investigating the fairness of the proposed sale of Surmodics to GTCR; the proposed sales price of $43.00 per share is far below the price target for Surmodics of Brooks O’Neil of Lake Street ($75.00) and Michael Petusky of Barrington ($71.00); read more at: https://wohlfruchter.com/cases/surmodics/

StockInvest_us Posted - 5 months ago

Signal alert: $SRDX - Overbought Trend Short (Overvalued) https://stockinvest.us/l/halpvqp44p

Thestocktraderhubzee Posted - 05/30/24

WATCHLIST MAY 30 2024. $SRDX Sidoti & Co. Downgrades Surmodics to Neutral, Announces $43 Price Target $CCL Carnival shares are trading lower after Truist Securities maintained a Hold rating on the stock and lowered its price target from $18 to $17. $NAT Jefferies Maintains Buy on Nordic American Tankers, Lowers Price Target to $5 $LXU Deutsche Bank Maintains Buy on LSB Industries, Raises Price Target to $11 $DKS B of A Securities Upgrades Dick's Sporting Goods to Buy, Raises Price Target to $240

E232BC Posted - 05/29/24

$SRDX If you're interested in a rare otc FDA 510K opportunity look into $RMSL - Unique patented CPAP mask like no other currently in the market. Major news on AI request submission released today. FDA has 30 days to respond. Chances of approval are extremely high. Can easily double current price on the run up alone. Sales and distribution to follow approval and additional masks in the pipeline. Long term goal is for a buyout from industry leaders (such as Philips, Resmed etc.) Feel free to DM with any questions.

OpenOutcrier Posted - 05/29/24

RECAP 5/29 Chatter: $UNH - Medicaid Risks RECAP 5/29 +Pos Comments: $DKS + BofA $LGF + Barrington $VZIO + Barrington RECAP 5/29 -Neg Comments: $SRDX - Sidoti $SRDX - Needham Live Breaking trading news www.openoutcrier.com

tradingtwenty Posted - 05/29/24

$SRDX has trended 3 times in the past 24 hours (based on 5 minute intervals). Latest press release on May 29, 2024 07:00 AM: Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing... Link: https://tradingtwenty.com/news/491617/surmodics-enters-into-definitive-agreement-to-be-acquired-by-gtcr-for-4300-per-share-in-cash-representing-an-approximate-equity-value-of-627-million

tradingtwenty Posted - 05/29/24

Top pre-market stock gainers: $RSLS $CCG $SYTA $SCPXD $SRDX 🔥 Link: https://tradingtwenty.com/dashboard/trending/past

DekmarTrades Posted - 05/29/24

Todays Top Gainers based off News/Filings! We are not seeing much as there is a lack of news and Stocks arent up big, Warrants are up! $TOIIW $BAERQ $APLMW $NAMSW ...... Stocks: $GVH $SCPXD $SRDX

MakingDreamsReality Posted - 05/29/24

PM mOOvers 👀 $IKNA -Ikena Oncology shares are trading higher after the company announced it will discontinue development of IK-930 and evaluate strategic options for both the Company and its development pipeline. $QBTS -D-Wave Quantum Set to Join Russell 3000® Index $TELL -Aethon Energy to Acquire Tellurian Integrated Upstream Assets $SRDX -Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million $BNAI - BEN Closes $4.95M Private Placement, Appoints Paul Chang To Co-CEO; Shares Spike Higher

DonCorleone77 Posted - 05/29/24

$SRDX Surmodics to be acquired by PE firm GTCR for $43 per share in cash Surmodics announced that it has entered into a definitive agreement to be acquired by GTCR, a private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the agreement, affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627M. The per-share acquisition price represents a 41.1% premium to Surmodics' 30-trading day volume-weighted average closing price through May 28 . Surmodics' Board of Directors has unanimously approved the transaction and resolved to recommend that stockholders vote in favor of the transaction... The transaction is expected to close in the second half of calendar year 2024, subject to customary closing conditions, including approval by Surmodics shareholders and required regulatory approval. It will be financed through a combination of committed equity from funds affiliated with GTCR and committed debt financing. Upon completion of the transaction, Surmodics will be a privately held company and its common stock will no longer be listed on The Nasdaq Stock Exchange.

DekmarTrades Posted - 05/29/24

Top Gainers this Morning from Hot News/Filings! Keep these plays on HIGH ALERT! $SCPXD $BTTX $SMLR $SRDX

Stock_Titan Posted - 05/29/24

$SRDX Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million https://www.stocktitan.net/news/SRDX/surmodics-enters-into-definitive-agreement-to-be-acquired-by-gtcr-qhutej2selyl.html